13 February 2019
The U.S. Food and Drug Administration (FDA) recently released the final guidance entitled “Public Warning and Notification of Recalls.” The announcement of the guidance has been published in the Federal Register on February 8, 2019.
For the fiscal year 2018, FDA reports a total of 7,420 recalls with 831 that were classified as the highest risk. Acording to the agency, FDA will routinely provide more information on recalls and other safety issues that have happened and also communicate more frequently and, in many cases, directly to consumers through the agency’s social media. Therefore, the final guidance for industry and FDA staff
FDA states that in accordance with the draft version of this guidance, the agency already issued alerts or consumer warnings related to many products (including valsartan, losartan and irbesartan).
PrintVaccine Rollout Even Worse than Expected
25 January 2021
Failure to launch? Half of drugs rolled out since 2004 didn't live up to sales forecasts: report
22 January 2021
Pharma ad agencies weigh in with Biden vaccine campaign advice
21 January 2021
The pandemic and the pharmaceutical world
21 January 2021